Novo Nordisk Presents Results of Concizumab in P-III (explorer7) Study for the Treatment of Haemophilia A or B at ISTH 2022
- The P-III (explorer7) study evaluates concizumab in a ratio (1:2) in 7133 males aged ≥12yrs. patients with haemophilia A or B with/out inhibitors
- The results showed an 86% reduction in treated spontaneous & traumatic bleeds, mean ABR of 1.7 vs 11.8 with no prophylaxis & overall median ABR was 0 vs 9.8, 63.6% vs 10.5% experienced no treated bleeds. The safety & tolerability profile was within the expected range with no thromboembolic events reported after treatment restart
- The company is expected to submit for regulatory approval of concizumab for prophylactic treatment of haemophilia A or B with inhibitors in H2’22 in the US & Japan and 2023 in the EU & the UK. The therapy is also being studied in (explorer10) paediatric study & is expected to be complete in 2026
Ref: GlobeNewswire | Image: Novo Nordisk
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.